Beyondspring (NASDAQ:BYSI)‘s stock had its “buy” rating restated by stock analysts at Maxim Group in a research note issued on Wednesday. They currently have a $52.00 price objective on the stock. Maxim Group’s target price would suggest a potential upside of 99.92% from the company’s current price.

The analysts wrote, “On January 29th, BeyondSpring hosted a KOL call to discuss its lead asset, Plinabulin. Dr. Douglas Blayney, a founding member of the NCCN neutropenia management guideline panel, spoke on the call regarding Plinabulin and the ongoing phase 2/3 trial, Study 105 for the prevention of docetaxel chemotherapy-induced neutropenia (CIN).””

Several other research firms have also commented on BYSI. HC Wainwright set a $60.00 price objective on shares of Beyondspring and gave the stock a “buy” rating in a research note on Thursday, October 26th. Zacks Investment Research lowered shares of Beyondspring from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Finally, Seaport Global Securities assumed coverage on shares of Beyondspring in a research note on Tuesday, December 5th. They set a “buy” rating and a $56.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $54.50.

Shares of Beyondspring (NASDAQ BYSI) opened at $26.01 on Wednesday. Beyondspring has a 1 year low of $16.55 and a 1 year high of $48.49.

Beyondspring (NASDAQ:BYSI) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.01. research analysts predict that Beyondspring will post -4.41 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Beyondspring stock. Tanaka Capital Management Inc. acquired a new position in shares of Beyondspring Inc (NASDAQ:BYSI) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring accounts for about 2.1% of Tanaka Capital Management Inc.’s holdings, making the stock its 16th biggest holding. Tanaka Capital Management Inc. owned 0.10% of Beyondspring as of its most recent filing with the Securities & Exchange Commission. 1.22% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2018/02/07/maxim-group-reiterates-buy-rating-for-beyondspring-bysi.html.

Beyondspring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.